Stock Split: Multibagger Stock Sets Record Date, Hits 52-Week High For 2nd Consecutive Day

Small cap stock operating in pharmaceuticals sector, Themis Medicare on Wednesday fixed October 10, 2023 as the record date for 1:10 stock split. Themis Medicare stock traded fresh 52-week high today. The small cap stock also recorded spurt in volume by more than 1.43 times. Themis Medicare shares also hit back-to-back 52-week high on September 20 and September 21. Themis Medicare gave 78% return in last 1-year and 428% return in last 3-years. Check details below:

Themis Medicare Sets Record Date For Stock Split: According to the BSE filing of Themis Medicare shares date September 20, "With reference to the captioned subject and in terms of Regulation 42 of the SEBI Listing Regulations, the Company has fixed Tuesday, 10th October, 2023 as the 'Record Date' for the purpose of determining the eligibility of Shareholders for the purpose of sub-division/split of every one fully paid-up Equity share having face value Rs. 10/- (Rupees Ten only) each in the authorised share capital of the Company, into 10 (ten) fully paid-up Equity shares having face value of Rs. 1/- (Rupee One only) each, as approved by the shareholders at the 53rd Annual General Meeting of the Company held on 9th September, 2023."

Themis Medicare Stock Outlook & Return: Current market price of Themis Medicare share is Rs 1746.85 per share with intraday gain of 2.30% or 39.30 points on BSE. Its 52-week high price is quoted at Rs 1794.75 per share and 52-week low price is Rs 875.10 per share, respectively. The company has a market capitalisation of Rs 1607.59 crore. Themis Medicare shares offered return of 50% in last 6-months, gained 432% in last 5-years, and soared 4066% in last 10-years.

Themis Medicare About: Themis is a research-based pharmaceutical company specializing in manufacture of a wide range of products for application areas like Pain Management, Critical Care and Anti-Infectives. We develop high response differentiated products through our platform technologies with a clear focus on patient benefit, according to its official website.

Disclaimer

The stock just highlights the stock split and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.